

- This retrospective cohort study compared the number of, and expenditures on, first-line intravitreal anti-vascular endothelial growth factor (VEGF) injections between U.S. patients who were treated with aflibercept or ranibizumab for wet age-related macular degeneration (AMD) between November 18, 2011 and April 30, 2013.
- Outcomes were measured within 6 and 12 month follow-up periods after anti-VEGF initiation.
- A total of 319 aflibercept patients and 1,054 ranibizumab patients were included in the 6-month analyses and 57 aflibercept and 374 ranibizumab patients were included in the 12-month analyses.
- Multivariable regression determined that, over the first 6 months and 12 months after the index date, neither the number of injections nor the expenditures on injections differed significantly between aflibercept patients and ranibizumab patients.

This summary slide represents the opinions of the authors, and not necessarily the opinions of the publisher or editorial board. This material has been peer reviewed. Sponsorship for this study and summary slide was funded by Genetech Inc. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online.